[A25-61] Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, ≥ 2 years, at least one non-class I mutation, excluding F508del and gating mutations) – Benefit assessment according to §35a Social Code Book V
Last updated 01.08.2025
Project no.:
A25-61
Commission:
Commission awarded on 02.05.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Cystic fibrosis (CF) in patients aged 2 years and older who have at least one non-class I mutation, excluding an F508del and gating mutation, in the cystic fibrosis transmembrane conductance regulator gene
- Patients aged 2 to 5 years: added benefit not proven
- Patients aged 6 to 17 years: hint of non-quantifiable added benefit
- Patients from 18 years of age: hint of major added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-61